PT  - JOURNAL ARTICLE
AU  - Tsiachris, Dimitrios
AU  - Kordalis, Athanasios
AU  - Antoniou, Christos-Konstantinos
AU  - Karanikola, Aikaterini-Eleftheria
AU  - Doundoulakis, Ioannis
AU  - Laina, Aggeliki
AU  - Xydis, Panagiotis
AU  - Tsioufis, Konstantinos
TI  - Durability of pulmonary vein isolation and feasibility and safety of additional intrapulmonary vein sleeve ablation by means of a circular pulsed-field ablation catheter. The PVI-PVA study
AID  - 10.1101/2025.10.22.25338592
DP  - 2025 Jan 01
TA  - medRxiv
PG  - 2025.10.22.25338592
4099  - http://medrxiv.org/content/early/2025/10/30/2025.10.22.25338592.short
4100  - http://medrxiv.org/content/early/2025/10/30/2025.10.22.25338592.full
AB  - Background Pulmonary vein isolation (PVI) constitutes the established strategy for atrial fibrillation (AF) ablation. With the advent of PV stenosis risk-free pulsed field ablation (PFA), we explored the feasibility and safety of additional ablation within PV sleeves (PVA). Moreover, we assessed the durability of PVI through PFA in a deep sedation setting, comparing a 3D Electroanatomical Mapping (3D-EAM)-based navigation approach with the standard fluoroscopy-based one.Methods In this single-center, first-in-human study (NCT07035288), 40 AF patients underwent first time PFA-based PVI+PVA (4 additional applications inside the PVs) between November 2024 and April 2025 using a circular array PFA catheter (PulseSelect, Medtronic, Minneapolis, MN), randomized to either 3D-EAM-based (Carto3 prime, J&J, Irvine, CA) or fluoroscopy-based navigation, in a propofol-based deep sedation setting. Rate of conversion from 3D-EAM to fluoroscopy-based navigation was recorded. First-pass isolation was assessed immediately post-ablation. Venography and 3D-EAM were performed at remapping at 2 to 3 months after the index procedure.Results No major procedure-related adverse events were noted, as well as no acute kidney injury, significant hemolysis or phrenic nerve palsy. First-pass isolation was successfully achieved in 95% of patients (3D-EAM: 95%, fluoroscopy: 95%, p=NS) and in 98.7% of PVs. Venography performed at remapping revealed no PV stenosis. PVI durability per patient was 92.5% (3D-EAM: 90%, fluoroscopy: 95%, p=NS) and per vein was 97.5% (3D-EAM: 97.5%, fluoroscopy: 97.5%, p=NS between navigation methods). Half of 3D-EAM cases were converted to fluoroscopy due to map shift.Conclusions PFA-based PVA is safe. Catheter performance, as depicted by 97.5% durable PVI, was such that adding a 3D-EAM system was not associated with improved efficacy and exhibited high conversion rate to fluoroscopy-based navigation in a deep sedation setting.Categories: electrophysiologySpecial Sections: Original articleRandomized clinical trial: NCT07035288Competing Interest StatementDimitris Tsiachris has been a member of advisory board for PulseSelect Catheter, received honoraria for lectures and presentations on PulseSelect Catheter and support for attending meetings Athanasios Kordalis and Konstantinos Tsioufis received honoraria for lectures and presentations on PulseSelect Catheter and support for attending meetingsClinical TrialNCT07035288Funding StatementThe present study was funded by Medtronic through the ERP-2024-13979Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of General Hospital of Athens, HippokratioI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available when requiredAFAtrial fibrillationPVspulmonary veinsPVIPulmonary vein isolationPFAPulsed field ablation3D-EAM3-dimensional electroanatomical mappingPVAPulmonary vein ablation